Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

So Hyun Park, BS, Ciaran M Lee, PhD, Yankai Zhang, PhD, Alicia Chang, MD, Vivien A Sheehan, MD PhD, Gang Bao, PhD

Blood (2018) 132 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2018-99-114241

Published: 2018

Journal Articles

Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease

So Hyun Park, BS, Ciaran M Lee, PhD, Daniel P. Dever, PhD, Timothy H Davis, BS, Joab Camarena, BS, Yankai Zhang, PhD, Matthew Porteus, MD PhD, Vivian A Sheehan, MD PhD, Gang Bao, PhD

Blood (2018) 132 (Supplement 1): 2192.

https://doi.org/10.1182/blood-2018-99-117371

Published: 2018

Journal Articles

Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates

Olivier Humbert, PhD, Stefan Radtke, PhD, Ray R Carillo, Anai M Perez, Sowmya Somashekar Reddy, Lauren E Schefter, Christopher Lux, MDPhD, Sowmya Pattabhi, PhD, Olivier Negre, PhD, Ciaran M Lee, PhD, Jennifer Adair, PhD, Christopher Peterson, PhD, Gang Bao, PhD, David J. Rawlings, MD, Andrew M. Scharenberg, MD, Hans-Peter Kiem, MD PhD

Blood (2018) 132 (Supplement 1): 806.

https://doi.org/10.1182/blood-2018-99-112996

Published: 2018

Journal Articles

Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease

Alicia Chang, MD, So Hyun Park, BS, Ciaran M Lee, PhD, Alireza Paikari, MD, Gang Bao, PhD, Vivien A Sheehan, MD PhD

Blood (2018) 132 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2018-99-117158

Published: 2018

Journal Articles

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Diogo Gomes-Silva, Madhuwanti Srinivasan, Sandhya Sharma, Ciaran M. Lee, Dimitrios L. Wagner, Timothy H. Davis, Rayne H. Rouce, Gang Bao, Malcolm K. Brenner, Maksim Mamonkin

Blood (2017) 130 (3): 285–296.

https://doi.org/10.1182/blood-2017-01-761320

Published: 2017

Includes: Supplemental data

Journal Articles

Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease

So Hyun Park, BS, Ciaran M Lee, PhD, Harshavardhan Deshmukh, MS, Gang Bao, PhD

Blood (2016) 128 (22): 4703.

https://doi.org/10.1182/blood.V128.22.4703.4703

Published: 2016

Journal Articles

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Blood (2016) 128 (22): 4708.

https://doi.org/10.1182/blood.V128.22.4708.4708

Published: 2016

NARROW

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease

Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates

Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Engineered Human Umbilical Cord Derived Erythroid Progenitor Cells (HUDEP2) with Sickle or β-Thalassemia Mutation: An in-Vitro System for Testing Pharmacological Induction of Fetal Hemoglobin

Highly Efficient Editing of the Beta-Globin Gene in Patient Derived Hematopoietic Stem and Progenitor Cells to Treat Sickle Cell Disease

Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates

Sickle Human Umbilical Cord Derived Erythroid Progenitor Cells (S-HUDEP2): An Ideal in-Vitro System for Screening Anti-Sickling Compounds for Sickle Cell Disease

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Therapeutic Crispr/Cas9 Genome Editing for Treating Sickle Cell Disease

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only